When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Ozempic, Trulicity among Medicare's priciest drugs, report finds

   www.aol.com/news/ozempic-trulicity-among-medic...

   About 53 million Americans were enrolled in a Medicare prescription drug plan in 2024. Enrollees who take the priciest drugs will get some relief this year with a $2,000 cap on drug costs.

3. Medicare targets popular weight loss drugs Ozempic, Wegovy ...

   www.aol.com/medicare-targets-popular-weight-loss...

   About 5.3 million people with Medicare prescription drug coverage used these medications from November 2023 through October 2024 at a cost of $41 billion to the government-funded health program ...

4. GSK to cap out-of-pocket inhaler costs in US - AOL

   www.aol.com/news/gsk-cap-pocket-inhaler-costs...

   The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...

5. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the US Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway ...

6. Umeclidinium bromide - Wikipedia

   en.wikipedia.org/wiki/Umeclidinium_bromide

   Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol ) [ 4 ] [ 5 ] and also as a triple-therapy ...

7. Vilanterol - Wikipedia

   en.wikipedia.org/wiki/Vilanterol

   Vilanterol is an ultra-long-acting β 2-adrenoceptor agonist which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). [1] [2] The combination is also approved for the treatment of asthma in Canada, Europe, Japan [3] and ...